Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) generates frequent news flow as an international biotechnology company focused on antibody medicines for cancer and other serious diseases. Company announcements highlight advances in its antibody platforms, late‑stage clinical programs, regulatory milestones and corporate transactions, offering investors and observers a detailed view of how its science translates into clinical and commercial progress.
Recent news has emphasized the expanding clinical profile of epcoritamab (EPKINLY), an IgG1‑bispecific antibody created using Genmab’s DuoBody technology. Genmab regularly reports data from Phase 1b/2 and Phase 3 trials in diffuse large B‑cell lymphoma, follicular lymphoma and Richter transformation, including monotherapy and combination regimens with standard treatments such as R‑CHOP, R‑mini‑CHOP, rituximab and lenalidomide, and bendamustine plus rituximab. These updates often include response rates, survival outcomes and safety findings from major oncology congresses.
News coverage also includes developments in Genmab’s wholly owned pipeline, such as updated data for rinatabart sesutecan (Rina‑S) in advanced endometrial cancer and the expansion of its clinical program into Phase 3 trials. Corporate strategy items, including the planned acquisition and subsequent tender offer for Merus N.V. to add petosemtamab to the portfolio, feature prominently in company announcements and SEC‑related communications.
In addition, Genmab reports on initiatives that shape how it conducts research and development, such as its partnership with Anthropic to deploy Claude‑powered agentic AI solutions to support clinical development operations. Visitors to this GMAB news page can review these company announcements, trial readouts, regulatory updates and transaction disclosures to follow how Genmab’s antibody platforms, collaborations and late‑stage assets evolve over time.
Genmab (Nasdaq: GMAB) has announced its plans to acquire Merus (Nasdaq: MRUS) in an all-cash transaction valued at approximately USD 8.0 billion, or USD 97.00 per share. The acquisition represents a 41% premium over Merus' closing price on September 26, 2025.
The strategic acquisition brings petosemtamab, a late-stage oncology asset with two FDA Breakthrough Therapy Designations for head and neck cancer, into Genmab's portfolio. The Phase 3 asset showed promising Phase 2 data at ASCO 2025, with superior overall response rates and progression-free survival compared to standard care. Genmab expects potential product launch in 2027, with projected annual sales of $1+ billion by 2029.
The transaction will be funded through cash and $5.5 billion in non-convertible debt. Genmab aims to achieve gross leverage below 3x within two years post-closing. The deal is expected to close by early Q1 2026 and become EBITDA accretive by end of 2029.
Genmab (NASDAQ: GMAB) announced updated results from its Phase 2 EPCORE® NHL-6 trial evaluating epcoritamab monotherapy in relapsed/refractory (R/R) DLBCL patients. The study demonstrated significant success in outpatient treatment, with 92% of patients receiving their first full dose in an outpatient setting.
Key efficacy results showed an overall response rate of 64.3% and complete response rate of 47.6% in patients treated after one prior line of therapy. For patients with two or more prior treatments, the response rates were 60.0% and 38.0% respectively. The safety profile remained consistent with previous studies, with manageable cytokine release syndrome (CRS) occurring in 40.2% of patients, primarily low-grade and resolving within a median of two days.
Genmab (NASDAQ: GMAB) announced that the FDA has granted Breakthrough Therapy Designation (BTD) to rinatabart sesutecan (Rina-S®) for treating adult patients with recurrent or progressive endometrial cancer who have disease progression after platinum-containing regimen and PD-(L)1 therapy.
The designation was supported by results from the Phase 1/2 RAINFOL™-01 trial, where 64 heavily pretreated patients with advanced or recurrent EC were treated with Rina-S. The drug is currently being evaluated as a single-agent treatment in the ongoing Phase 1/2 RAINFOL™-01 trial and will be further studied in a planned Phase 3 trial.
Rina-S is a folate receptor alpha-directed, TOPO1-inhibitor antibody-drug conjugate (ADC) that is also being evaluated in other clinical trials, including the Phase 3 RAINFOL-02 trial in ovarian cancer.
Genmab (NASDAQ: GMAB) announced positive results from its Phase 3 EPCORE® FL-1 trial for epcoritamab combined with rituximab and lenalidomide (R2) in treating relapsed/refractory follicular lymphoma. The trial met both primary endpoints with significant improvements in Overall Response Rate (95.7%, p<0.0001) and Progression-Free Survival (HR 0.21, p<0.0001), reducing disease progression risk by 79%.
The FDA has accepted a priority review for the supplemental Biologics License Application (sBLA) with a target action date of November 30, 2025. If approved, this combination would become the first bispecific antibody regimen available as a second-line treatment for R/R FL patients. The safety profile aligned with known individual regimens with no new safety signals observed.
- First disclosure of Phase 1/2 trial results for rinatabart sesutecan (Rina-S®), a novel antibody-drug conjugate, in patients with recurrent/advanced endometrial cancer
- Presentation of long-term follow-up data from the Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory DLBCL, focusing on patients maintaining complete response at 2 years
The company will host a virtual investor update on June 2 at 4:00 PM CDT to review the Rina-S data. The presentations demonstrate Genmab's commitment to developing alternative treatment options, particularly for endometrial cancer, which has rising mortality rates and limited treatment options.
Two oral presentations will feature data from:
- EPCORE NHL-2 trial: evaluating epcoritamab plus R-ICE in relapsed/refractory DLBCL patients
- EPCORE NHL-5 trial: studying epcoritamab plus pola-R-CHP in previously-untreated DLBCL patients
Additional notable presentations include three-year follow-up data from the EPCORE NHL-1 and NHL-3 trials for epcoritamab monotherapy in R/R DLBCL and FL patients. The research will also be presented at the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland.
Genmab A/S (NASDAQ: GMAB) announced that the European Commission has approved TIVDAK® (tisotumab vedotin) for treating adult patients with recurrent or metastatic cervical cancer who experienced disease progression after systemic therapy. TIVDAK is the first and only antibody-drug conjugate (ADC) approved for this indication in the EU.
The approval is based on the Phase 3 innovaTV 301 trial results, where TIVDAK demonstrated:
- 30% reduction in death risk compared to chemotherapy
- Median overall survival of 11.5 months vs 9.5 months for chemotherapy
- 33% reduction in disease progression risk
Common adverse reactions (≥25%) included peripheral neuropathy (39%), nausea (37%), epistaxis (33%), conjunctivitis (32%), alopecia (31%), anaemia (27%), and diarrhoea (25%).